NOV 17, 202658 MINS READ
Creatine phosphate (N-phosphocreatine, phosphocreatine) is a high-energy phosphagen compound with the molecular formula C₄H₁₀N₃O₅P and a molecular weight of approximately 211.11 g/mol. The molecule contains a guanidinium group linked to an N-methyl glycine moiety, with a phosphate group attached to the nitrogen atom via a high-energy phosphoramidate bond 2. This bond possesses a standard free energy of hydrolysis (ΔG°') of approximately -43.1 kJ/mol at pH 7.4 and 25°C, which is significantly higher than that of ATP (-30.5 kJ/mol), making CP an efficient energy reservoir 1,7.
CP exists predominantly in its anionic form at physiological pH (7.2-7.4), with a pKa of approximately 4.5 for the phosphate group 4. The compound demonstrates excellent aqueous solubility, typically exceeding 50 mg/mL at neutral pH, and exhibits stability in buffered solutions when stored at 2-8°C 5. Commercial preparations of creatine phosphate are commonly supplied as the disodium tetrahydrate salt (Na₂CP·4H₂O), which provides enhanced stability during storage and facilitates accurate formulation in biochemical assays 4,10.
The reversible nature of the CP-ATP interconversion reaction is central to cellular bioenergetics. At physiological pH 7.4, the equilibrium of the creatine kinase-catalyzed reaction (CP + ADP ⇌ Creatine + ATP) is shifted toward ATP formation, with an equilibrium constant (Keq) of approximately 160 1,7. This thermodynamic favorability enables rapid ATP regeneration during periods of high energy demand, maintaining ATP/ADP ratios that support optimal cellular function.
Creatine kinase exists in multiple isoenzyme forms, each exhibiting tissue-specific expression patterns and distinct subcellular localizations 2,18. The cytosolic isoforms are dimeric proteins composed of two subunit types: M (muscle) and B (brain), which combine to form three major isoenzymes:
The catalytic mechanism of creatine kinase involves a sequential ordered bi-bi reaction mechanism, wherein substrates bind and products are released in a defined sequence 2,7. The enzyme requires divalent metal ions (Mg²⁺ or Mn²⁺) as cofactors, which coordinate with the β- and γ-phosphate groups of ATP/ADP to form catalytically competent metal-nucleotide complexes 4,16. Kinetic studies have established Km values for CP ranging from 1-5 mM and for ADP from 0.1-0.5 mM under physiological conditions, indicating high substrate affinity 7,18.
Structural analyses reveal that the active site of creatine kinase contains critical residues that facilitate phosphoryl transfer through a direct in-line transfer mechanism 2. Thiol-containing residues, particularly cysteine residues near the active site, are essential for catalytic activity and are susceptible to oxidative inactivation, necessitating the inclusion of thiol-protecting agents (e.g., N-acetylcysteine, dithiothreitol) in biochemical assays and therapeutic formulations 4,5,9.
The CK/CP system functions as a temporal energy buffer, maintaining stable ATP concentrations during transient periods of high energy demand 2,8. In skeletal muscle during intense contraction, ATP consumption rates can increase 100-fold within milliseconds. Under these conditions, the CK reaction rapidly regenerates ATP from CP, preventing significant ATP depletion and maintaining the ATP/ADP ratio above 10:1, which is critical for sustaining contractile function and preventing cellular injury 1,7.
Quantitative studies in isolated muscle preparations have demonstrated that CP stores can sustain maximal ATP turnover rates for 5-10 seconds before significant depletion occurs 2. The total creatine pool (CP + free creatine) in skeletal muscle typically ranges from 120-140 mmol/kg dry weight, with the CP fraction representing 60-70% of this pool at rest 7,18. During high-intensity exercise, CP levels can decrease by 50-60% within 10 seconds, while ATP levels remain relatively stable (declining by only 10-20%), illustrating the buffering capacity of the system 2.
Beyond temporal buffering, the CK/CP system facilitates spatial energy distribution through the "phosphocreatine shuttle" or "creatine kinase circuit" 2,8. This model proposes that mitochondrial CK isoforms (located in the intermembrane space) generate CP using mitochondrially-produced ATP, and this CP then diffuses to cytosolic sites of ATP consumption, where cytosolic CK isoforms regenerate ATP locally 2. This mechanism is particularly important in cardiomyocytes and neurons, where ATP consumption sites (e.g., myofibrils, ion pumps) may be spatially distant from mitochondria.
Experimental evidence supporting this model includes:
The CK/CP system influences cellular signaling pathways through multiple mechanisms 1,2. ATP generated by the CK reaction serves as a substrate for adenylyl cyclase, which produces cyclic AMP (cAMP), a critical second messenger regulating protein kinase A (PKA) signaling cascades 1. Elevated cAMP levels modulate numerous cellular processes, including:
Additionally, the CK/CP system directly influences ion transport by maintaining local ATP concentrations near ATP-dependent ion pumps (Na⁺/K⁺-ATPase, Ca²⁺-ATPase, H⁺-ATPase) 2,7. Disruption of CK function impairs ion homeostasis, leading to cellular dysfunction and increased susceptibility to ischemic injury 8.
Measurement of CK activity in biological samples (serum, plasma, tissue homogenates) is essential for clinical diagnosis and research applications 4,7,10. The most widely employed methods utilize coupled enzyme systems that link CK activity to the production or consumption of spectrophotometrically detectable species 7,18.
The standard coupled enzyme assay for CK involves the following reaction sequence 7,10,18:
The rate of NADPH formation, monitored by absorbance increase at 340 nm, is directly proportional to CK activity 7,10. Optimal assay conditions include:
Alternative coupled enzyme systems have been developed to address limitations of the HK/G6PDH method, including:
Phosphoglycerate kinase (PGK)/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) system: This approach offers improved reagent stability and reduced interference from glutathione reductase present in some samples 18. The reaction sequence involves PGK-catalyzed conversion of ATP and 3-phosphoglycerate to ADP and 1,3-bisphosphoglycerate, followed by GAPDH-catalyzed reduction of 1,3-bisphosphoglycerate using NADH, which is monitored at 340 nm 18.
Luciferase-based bioluminescent assay: This highly sensitive method employs firefly luciferase to detect ATP generated by the CK reaction 6,9. The assay includes CK-M-specific antibodies to selectively inhibit CK-MM, enabling specific measurement of CK-B subunit activity 6. Optimal conditions include pH 5.8-7.5, 1-10 mM AMP, and at least 50 units of luciferase per test, with diadenosine pentaphosphate (10-50 μM) to inhibit adenylate kinase 9.
Differentiation of CK isoenzymes is critical for accurate diagnosis of tissue-specific injury 1,4,15. Electrophoretic separation remains a gold standard method, utilizing agarose gel or cellulose acetate membranes to resolve CK-MM, CK-MB, and CK-BB based on charge differences 4. Following electrophoresis, CK isoenzymes are visualized using the coupled enzyme reagent described above, with NADPH fluorescence or tetrazolium salt reduction producing detectable bands 4,11.
Improved electrophoretic reagents incorporate phosphogluconate dehydrogenase (decarboxylating) at 500-3,000 IU/L to enhance sensitivity and reduce background interference 4. Optimal reagent composition includes 15 mM creatine phosphate, 4 mM ADP, 20 mM glucose, 6,500 IU/L hexokinase, 7,500 IU/L G6PDH, 20 mM N-acetylcysteine, 15 mM magnesium acetate, 5 mM AMP, 4 mM NADP⁺, and 1,500 IU/L phosphogluconate dehydrogenase (decarboxylating) in MOPSO buffer (pH 6.5-7.0) 4.
Immunoinhibition assays provide an alternative approach for CK-MB quantification 15. These methods employ antibodies specific for the CK-M subunit to inhibit CK-MM and the M subunit of CK-MB, allowing measurement of residual CK-B activity, which is then used to calculate CK-MB concentration 15. Metal ion-based selective inhibition has also been explored, with aluminum ions (Al³⁺) preferentially inhibiting CK-MB while activating or minimally affecting CK-MM, enabling differential measurement in human serum 15.
Clinical reference ranges and diagnostic thresholds for CK isoenzymes include:
A novel therapeutic approach involves combined administration of exogenous CP and CPK for treatment of atherosclerotic plaques 1. The rationale is based on the hypothesis that atherosclerotic plaques contain dormant or energy-depleted enzymes (e.g., lipoprotein lipase, cholesterol esterase) that, when reactivated by local ATP provision, can mobilize lipid deposits and promote plaque regression 1.
The proposed mechanism involves:
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| ARTCELL INVEST LTD. | Treatment of atherosclerotic plaques in arterial walls, cardiovascular disease management, and therapeutic intervention for patients with lipid-rich vascular deposits requiring enzymatic plaque regression. | CP-CPK Atherosclerosis Therapy | Combined exogenous creatine phosphate and creatine phosphokinase provide localized ATP generation to reactivate plaque-resident enzymes, enabling lipolytic effects on triglyceride-rich lipoproteins and cholesterol mobilization from atherosclerotic plaques without direct negative inotropic effects. |
| DANA-FARBER CANCER INSTITUTE INC. | Prevention and treatment of metabolic disorders including hyperglycemia, insulin-dependent diabetes mellitus, impaired glucose tolerance, hyperinsulinemia, and diabetes-related complications in patients with glucose metabolic dysregulation. | Creatine Analogue Metabolic Therapy | Creatine phosphate and cyclocreatine modulate the creatine kinase/creatine phosphate energy system to regulate glucose metabolism, improving insulin sensitivity and glucose homeostasis through enhanced cellular ATP regeneration and cAMP-mediated signaling cascades. |
| BECKMAN INSTRUMENTS INC. | Clinical diagnostic laboratories for differential diagnosis of tissue-specific injuries including myocardial infarction (CK-MB elevation), skeletal muscle damage (CK-MM), and neurological conditions, enabling accurate biomarker-based disease detection. | CK Isoenzyme Electrophoresis Reagent | Optimized reagent containing 15mM creatine phosphate, coupled enzymes (hexokinase 6500 IU/L, G6PDH 7500 IU/L), phosphogluconate dehydrogenase (1500 IU/L), and N-acetylcysteine (20mM) enables enhanced sensitivity and reduced background interference for accurate CK-MM, CK-MB, and CK-BB isoenzyme separation and quantification. |
| ROCHE DIAGNOSTICS GMBH | Clinical chemistry analyzers and diagnostic laboratories requiring robust, stable creatine kinase activity measurement in serum and plasma samples for cardiovascular and muscular disease diagnosis with extended reagent shelf-life. | Alternative Hexose CK Assay System | Novel coupled enzyme method utilizing hexokinase with alternative hexose substrates and hexose-6-phosphate dehydrogenases (other than G6PDH) or isomerization pathways, providing improved reagent stability and reduced interference from endogenous glutathione reductase in biological samples. |
| MITSUBISHI PETROCHEMICAL CO. LTD. | Clinical diagnostic applications requiring long-term reagent stability for creatine kinase activity measurement in progressive muscular dystrophy and myocardial infarction diagnosis, particularly in settings where frequent reagent preparation is impractical. | PGK-GAPDH CK Measurement System | Phosphoglycerate kinase and glyceraldehyde-3-phosphate dehydrogenase coupled enzyme system with superior storage stability compared to traditional hexokinase method, eliminating interference from glutathione reductase and enabling accurate CK activity measurement using NADH oxidation monitoring at 340nm. |